The new US precision medicine initiative1 has been made possible by improvement and price reduction in genome sequencing, as well as advances in multiple sectors of biotechnology. The initiative includes 2 components: a focus on cancer intended to spur development of new targeted cancer treatments, and a proposal for establishing a national cohort of at least 1 million people to explore genetic and environmental determinants of health and disease. The success of this initiative requires a public health perspective to help ensure generalizability, assess methods of implementation, focus on prevention, and provide an appropriate balance between generation of long-term knowledge and short-term health gains.
Khoury MJ, Evans JP. A Public Health Perspective on a National Precision Medicine CohortBalancing Long-term Knowledge Generation With Early Health Benefit. JAMA. 2015;313(21):2117-2118. doi:10.1001/jama.2015.3382